73例西妥昔单抗不良反应文献分析  

Literature analysis of 73 cases of adverse drug reactions induced by cetuximab

作　　者：王鑫璐 景啸澜 曲晓宇[1] 李艳娇[1] WANG Xin-lu;JING Xiao-lan;QU Xiao-yu;LI Yan-jiao(Department of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China;Department of Pharmacy,Dongliao People's Hospital,Liaoyuan 136200,China)

机构地区：[1]吉林大学第一医院药学部,吉林长春130021 [2]东辽县人民医院药剂科,吉林辽源136200

出　　处：《中国药物应用与监测》2021年第4期252-255,共4页Chinese Journal of Drug Application and Monitoring

基　　金：国家自然科学基金青年科学基金项目(81803608)。

摘　　要：目的:探讨与分析西妥昔单抗所致药品不良反应(ADR)发生的规律及特点,旨为临床合理用药提供依据。方法:检索中国知网、万方、维普、PubMed、Web of Science等数据库,对所收集的西妥昔单抗致ADR相关文献进行统计与分析。结果:共检索到73例西妥昔单抗所致ADR的个例报道,以男性患者为主(53例,72.60%),多数患者年龄为61~70岁(29例,39.72%);西妥昔单抗多用于联合FOLFOX或FOLFIRI方案作为结直肠癌一线治疗方案(55例,75.34%);用药后60 min~1周发生ADR者最多(23例,31.50%),累及皮肤系统的ADR最为常见(27例,36.99%),其次为全身性损害(12例,16.44%)。结论:临床应用西妥昔单抗时,医师、患者、药师等应警惕相关ADR的发生,加强药物治疗的安全性监测。Objective:To explore and analyze the regularity and characteristics of adverse drug reaction(ADR)caused by cetuximab in order to provide references for rational drug use in clinic.Methods:Literature related to ADR induced by cetuximab were collected from CNKI,Wanfang,VIP,PubMed,and Web of Science were statistically analyzed.Results:A total of 73 case reports of ADR induced by cetuximab were enrolled in this study,among which most patients were males(53 cases,72.60%).The proportion of patients aged 61–70 years old was the highest(29 cases,39.72%).55 cases(75.34%)used cetuximab combined with FOLFOX regimen or FOLFIRI regimen as the first-line therapy for colorectal cancer.Most ADR(23 cases,31.50%)occurred within 60 min-1 week after administration.The most common system/organ involved in ADR induced by cetuximab was skin system(27 cases,36.99%)which was followed by systemic damage(12 cases,16.44%).Conclusion:Physicians,patients and pharmacists should be alert to the occurrence of ADR induced by cetuximab and strengthen the safety monitoring of drug treatment.

关 键 词：西妥昔单抗 药品不良反应 文献分析 

分 类 号：R969.3[医药卫生—药理学] R979.1[医药卫生—药学]